Home › Companies › PMVP

PMV Pharmaceuticals, Inc.

PMVP Lead: Phase 2 3 Biotech Distilled articles ↓

Oncology Small Molecule

Most recent annual filing: 2026-03-06

Pipeline (7 active programs)

rezatapopt

PC14586

Small Molecule Target: p53 Y220C, p53, TP53 Y220C

Technology platforms

Precision Oncology Platform

Small molecule discovery and development platform targeting p53 mutations and p53-related cancers; leverages structural biology, assays, and biomarkers to identify and optimize selective small molecules that structurally correct specific mutant p53 proteins to restore wild-type function; disease focus is tumor-agnostic oncology defined by p53 genomic alterations.

Targets: p53

Biotech Distilled coverage (3)

2026-05-12 UPDATE: PMV Pharma (PMVP) - The ORR Shrinks, The NEJM Validates, The Clock Tightens
2026-03-08 UPDATE: PMV Pharma (PMVP) - The Data Gets Stronger... 🔒 Paid
2026-02-16 PMV Pharmaceuticals (PMVP): Scientific Deep Dive for Rezatapopt 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.